chronic
obstruct
pulmonari
diseas
copd
major
public
health
problem
one
lead
global
caus
mortal
come
decad
much
morbid
mortal
health
care
cost
copd
attribut
acut
exacerb
commonest
caus
respiratori
infect
respiratori
virus
frequent
detect
copd
exacerb
direct
proof
caus
relationship
lack
develop
model
copd
exacerb
use
experiment
rhinoviru
infect
copd
patient
establish
caus
relationship
viru
infect
exacerb
addit
determin
molecular
mechan
link
viru
infect
copd
exacerb
identifi
potenti
new
therapeut
target
new
data
stimul
research
role
antivir
agent
potenti
treatment
copd
exacerb
test
antivir
agent
hamper
lack
small
anim
model
rhinoviru
infect
experiment
rhinoviru
infect
healthi
volunt
use
test
treatment
common
cold
experiment
rhinoviru
infect
copd
subject
offer
prospect
model
use
evalu
effect
new
treatment
virusinduc
copd
exacerb
provid
essenti
data
use
make
decis
regard
larg
scale
clinic
trial
chronic
obstruct
pulmonari
diseas
copd
defin
treatabl
prevent
diseas
characteris
progress
airflow
limit
enhanc
airway
inflammatori
respons
vestbo
et
al
common
chronic
respiratori
condit
adult
estim
million
peopl
moder
sever
copd
result
million
death
copd
develop
respons
cumul
exposur
inhal
noxiou
particl
gase
trigger
patholog
respons
lung
eventu
lead
develop
diseas
number
aetiolog
agent
associ
develop
copd
western
countri
preval
copd
strongli
relat
cigarett
smoke
tobacco
smoke
main
aetiolog
agent
survey
carri
develop
nation
becom
appar
relationship
cigarett
smoke
copd
less
strong
countri
buist
et
al
menez
et
al
risk
factor
contribut
develop
copd
includ
exposur
burn
biomass
fuel
outdoor
air
pollut
respiratori
infect
copd
characteris
number
patholog
chang
lung
includ
parenchym
destruct
emphysema
inflamm
larg
airway
chronic
bronchiti
inflamm
destruct
small
airway
bronchiol
mucou
hypersecret
hogg
timen
patholog
chang
lead
characterist
physiolog
abnorm
airflow
obstruct
manifest
reduct
forc
expiratori
volum
fev
reduct
ratio
fev
forc
expiratori
volum
fvc
hyperinfl
impair
ga
exchang
eventu
lead
respiratori
failur
three
main
process
lung
drive
develop
progress
diseas
name
pulmonari
inflamm
oxid
stress
proteaseantiproteas
imbal
exposur
inhal
irrit
cigarett
smoke
trigger
inflammatori
respons
lung
individu
develop
copd
respons
exagger
studi
compar
smoker
without
copd
demonstr
greater
number
neutrophil
macrophag
cell
lung
copd
patient
decram
et
al
di
stefano
et
al
inflammatori
cell
releas
host
biolog
mediat
includ
proteas
neutrophil
elastas
matrix
metalloproteas
whilst
time
antiproteas
defenc
lung
impair
pon
et
al
proteas
antiproteas
imbal
result
uninhibit
proteolyt
activ
destruct
lung
parenchyma
high
level
reactiv
oxygen
speci
gener
copd
exogen
sourc
tobacco
smoke
endogen
sourc
inflammatori
cell
overwhelm
lung
antioxid
defenc
oxid
stress
result
induc
multipl
biolog
effect
includ
induct
proinflammatori
cytokin
chemokin
mucou
hypersecret
activ
proteas
damag
cellular
compon
includ
phospholipid
protein
nucleic
acid
chiba
et
al
therefor
process
airway
inflamm
oxid
stress
proteas
excess
interlink
contribut
develop
copd
although
copd
develop
respons
inhal
noxiou
agent
diseas
develop
appear
autonom
origin
stimulu
studi
exsmok
copd
demonstr
airway
inflamm
indistinguish
copd
patient
continu
smoke
gambl
et
al
therefor
suggest
mechan
autoimmun
infect
may
perpetu
ongo
inflamm
copd
even
exposur
initi
agent
remov
decram
et
al
copd
enorm
public
health
problem
impact
expect
increas
futur
copd
fifth
lead
caus
death
worldwid
predict
lead
caus
death
mather
loncar
copd
develop
mani
year
exposur
relev
aetiolog
agent
therefor
current
preval
copd
reflect
exposur
risk
factor
occur
previou
decad
western
countri
preval
copd
expect
remain
stabl
year
despit
reduct
smoke
rate
reflect
previou
smoke
rate
age
popul
improv
therapi
respiratori
cardiovascular
diseas
reduc
mortal
copd
feenstra
et
al
much
increas
global
preval
copd
futur
expect
occur
middleincom
countri
larg
popul
china
india
turkey
south
africa
indonesia
smoke
rate
countri
remain
high
also
high
burden
risk
factor
use
biomass
fuel
outdoor
pollut
respiratori
infect
therefor
countri
perfect
storm
risk
factor
contribut
continu
global
epidem
copd
forese
futur
finney
et
al
van
zyl
smit
et
al
copd
patient
experi
vari
level
chronic
symptom
punctuat
period
sustain
acut
deterior
experi
increas
dyspnoea
sputum
product
sputum
purul
cough
episod
term
acut
exacerb
associ
increas
airflow
limit
dynam
hyperinfl
result
respiratori
failur
occurr
exacerb
increas
increas
sever
diseas
patient
experi
frequent
exacerb
exacerb
consider
impact
patient
healthcar
provid
acut
episod
reduct
exacerb
key
therapeut
goal
copd
copd
exacerb
associ
consider
mortal
exacerb
requir
hospit
admiss
inhospit
mortal
rate
almagro
et
al
connor
et
al
groenewegen
et
al
mortal
rate
rang
almagro
et
al
connor
et
al
groenewegen
et
al
exacerb
associ
fall
lung
function
frequent
prolong
lung
function
may
return
baselin
valu
sever
week
patient
seemung
et
al
frequent
exacerb
associ
acceler
declin
lung
function
anzueto
et
al
celli
et
al
donaldson
et
al
kanner
et
al
impair
qualiti
life
seemung
et
al
increas
likelihood
becom
housebound
healthcar
cost
econom
impact
copd
exacerb
enorm
unit
state
copd
exacerb
account
hospit
estim
cost
us
billion
perera
et
al
therefor
prevent
copd
exacerb
major
therapeut
target
major
unmet
need
copd
manag
nonpharmacolog
treatment
prevent
exacerb
includ
smoke
cessat
influenza
pneumococc
vaccin
pulmonari
rehabilit
mainstay
pharmacolog
therapi
inhal
bronchodil
inhal
corticosteroid
ic
clinic
trial
demonstr
treatment
reduc
exacerb
calverley
et
al
wedzicha
et
al
although
efficaci
ic
continu
debat
barn
suissa
barn
treatment
without
advers
effect
evid
suggest
ic
use
associ
increas
risk
pneumonia
copd
barn
cate
singanayagam
et
al
treatment
establish
exacerb
includ
bronchodil
system
corticosteroid
antibiot
clinic
benefit
modest
associ
consider
side
effect
therefor
effect
treatment
prevent
treatment
copd
exacerb
urgent
need
patholog
featur
stabl
copd
well
describ
patholog
exacerb
less
well
defin
exacerb
associ
increas
airflow
obstruct
hyperinfl
respiratori
failur
common
featur
sever
exacerb
commonli
state
airway
inflamm
increas
exacerb
mackay
hurst
close
examin
literatur
reveal
result
studi
far
consist
studi
report
increas
inflammatori
cell
mediat
exacerb
bathoorn
et
al
fujimoto
et
al
mercer
et
al
papi
et
al
wherea
other
bhowmik
et
al
roland
et
al
seemung
et
al
role
oxid
stress
copd
exacerb
also
unclear
increas
antczak
et
al
biernacki
et
al
dekhuijzen
et
al
drost
et
al
oudijk
et
al
tsoumakid
et
al
unchang
level
marker
oxid
stress
report
exacerb
kersul
et
al
koutsokera
et
al
van
beurden
et
al
number
sourc
variabl
studi
copd
exacerb
account
conflict
result
includ
differ
aetiolog
exacerb
sever
variat
time
present
effect
treatment
overcom
issu
challeng
order
develop
new
target
treatment
exacerb
much
better
understand
mechanist
pathway
copd
exacerb
requir
exacerb
associ
respiratori
infect
histor
bacteri
infect
consid
main
infect
caus
reflect
high
use
antibiot
exacerb
sandhu
et
al
epidemiolog
data
long
suggest
link
copd
exacerb
viru
infect
exacerb
occur
commonli
autumn
winter
month
half
twothird
patient
report
coryz
symptom
exacerb
falsey
et
al
hurst
et
al
seemung
et
al
howev
older
studi
respiratori
virus
could
detect
exacerb
buscho
et
al
murphi
sethi
smith
et
al
appar
confirm
convent
wisdom
exacerb
relat
bacteri
infect
studi
evalu
role
viru
infect
use
cultur
serolog
test
diagnost
tool
avail
time
sensit
test
low
particularli
rhinovirus
diagnost
method
base
polymeras
chain
reaction
pcr
amplif
detect
viral
nucleic
acid
significantli
sensit
detect
virus
respiratori
tract
compar
cultur
serolog
beckham
et
al
sethi
develop
pcrbase
diagnost
led
reevalu
role
respiratori
virus
copd
exacerb
recent
studi
use
pcr
gener
report
higher
detect
rate
compar
older
studi
preval
virus
copd
exacerb
vari
tabl
comparison
studi
difficult
due
differ
exacerb
sever
sampl
collect
sputumnasalnasopharyng
inclus
pcr
new
virus
human
metapneumoviru
bocaviru
recent
studi
howev
major
studi
frequent
identifi
virus
rhinovirus
influenza
respiratori
syncyti
viru
rsv
also
commonli
detect
virus
identifi
much
less
frequent
includ
parainfluenza
virus
coronavirus
adenovirus
human
metapneumovirus
studi
carri
europ
apart
one
dimopoulo
et
al
rhinovirus
common
virus
wherea
viral
aetiolog
exacerb
asia
north
america
appear
divers
whether
due
differ
circul
virus
differ
influenza
vaccin
uptak
region
unknown
although
studi
demonstr
associ
viru
infect
copd
exacerb
prove
causal
relationship
pcr
detect
viral
nucleic
acid
therefor
prove
presenc
live
replic
viru
demonstr
lower
airway
inflamm
respons
viru
infect
would
provid
evid
caus
role
virus
copd
exacerb
would
provid
evid
host
immun
respons
infect
convers
lack
inflammatori
respons
would
suggest
presenc
viru
simpli
secondari
event
epiphenomenon
studi
investig
conflict
result
report
viru
infect
associ
inflammatori
respons
rohd
et
al
seemung
et
al
wherea
other
bafadhel
et
al
hurst
et
al
pant
et
al
evid
favour
caus
relationship
provid
case
control
studi
demonstr
higher
viru
detect
rate
higher
viru
load
exacerb
compar
stabl
state
quint
et
al
studi
includ
control
group
tabl
therefor
although
respiratori
virus
detect
copd
exacerb
gener
greater
frequenc
stabl
copd
definit
causal
relationship
viru
infect
exacerb
establish
improv
diagnost
antivir
therapi
make
treatment
viru
infect
realist
possibl
near
futur
therefor
establish
role
respiratori
virus
copd
exacerb
longer
sole
academ
interest
definit
proof
respiratori
virus
caus
exacerb
alway
difficult
obtain
studi
naturallyoccur
viru
infect
asthma
respiratori
diseas
share
mani
featur
copd
includ
occurr
acut
exacerb
commonli
associ
detect
respiratori
virus
johnston
et
al
role
respiratori
viru
infect
asthma
exacerb
well
establish
part
due
use
experiment
rhinoviru
infect
model
virusinduc
asthma
exacerb
inocul
care
select
asthmat
volunt
rhinoviru
induc
clinic
featur
asthma
exacerb
bardin
et
al
studi
provid
import
insight
mechan
link
viru
infect
asthma
exacerb
gern
et
al
messag
et
al
moreov
experiment
rhinoviru
infect
studi
contribut
develop
novel
treatment
asthma
exacerb
identif
interferon
defici
asthmat
observ
led
develop
inhal
interferonb
treatment
virusinduc
asthma
exacerb
demonstr
efficaci
phase
ii
clinic
trial
publish
recent
confer
abstract
boxal
et
al
experiment
rhinoviru
infect
asthma
carri
number
differ
group
excel
safeti
record
bardin
et
al
gern
et
al
grunberg
et
al
view
frequent
detect
rhinovirus
copd
exacerb
group
aim
establish
whether
experiment
rhinoviru
infect
could
use
develop
similar
model
copd
howev
despit
excel
safeti
record
experiment
rhinoviru
infect
asthma
exist
number
concern
experiment
infect
copd
copd
patient
differ
markedli
asthma
patient
older
current
exsmok
impair
lung
function
airflow
obstruct
revers
factor
potenti
result
sever
respons
rhinoviru
infect
therefor
carri
small
pilot
studi
evalu
effect
safeti
inocul
low
dose
rhinoviru
subject
moder
copd
gold
stage
ii
subject
kept
daili
diari
card
record
upper
respiratori
symptom
cold
symptom
lower
respiratori
symptom
cough
sputum
volum
purul
wheez
breathless
typic
symptom
copd
exacerb
higher
score
indic
sever
valu
mean
se
p
vs
baselin
p
vs
baselin
p
copd
vs
control
p
copd
vs
control
p
copd
vs
control
mallia
et
al
reprint
permiss
american
thorac
societi
symptom
follow
rhinoviru
infect
subject
develop
symptomat
cold
increas
lower
respiratori
symptom
accompani
increas
airflow
obstruct
increas
inflammatori
marker
detect
rhinoviru
nucleic
acid
nasal
lavag
advers
event
sever
exacerb
requir
treatment
hospitalis
pneumonia
subject
recov
complet
therefor
first
demonstr
experiment
rhinoviru
infect
copd
subject
safe
induc
typic
clinic
featur
copd
exacerb
follow
small
studi
repeat
procedur
larger
group
copd
subject
togeth
group
smoker
without
copd
order
evalu
safeti
rhinoviru
infect
investig
mechan
virusinduc
exacerb
success
demonstr
rhinoviru
inocul
copd
subject
induc
cold
increas
lower
respiratori
symptom
time
cours
upper
lower
respiratori
symptom
shown
fig
cold
symptom
occur
earli
peak
day
postinocul
fig
wherea
lower
respiratori
symptom
occur
later
peak
day
prolong
take
week
return
baselin
level
fig
mirror
copd
patient
often
report
naturallyoccur
exacerb
ie
exacerb
frequent
preced
upper
respiratori
tract
infect
noncopd
subject
also
increas
lower
respiratori
symptom
sever
prolong
copd
group
analys
individu
symptom
differ
group
symptom
cough
sputum
copd
subjetc
report
increas
breathless
fig
breathless
key
defin
symptom
copd
exacerb
therefor
rhinoviru
infect
caus
acut
bronchiti
noncopd
subject
patient
copd
result
greater
physiolog
impair
manifest
acut
exacerb
confirm
signific
increas
airflow
obstruct
copd
subject
fig
use
quantit
pcr
measur
viru
load
analys
relationship
symptom
viru
replic
rhinoviru
nucleic
acid
detect
nasal
lavag
fluid
averag
day
postinocul
peak
day
nasal
lavag
day
sputum
fig
kinet
viru
load
airway
provid
power
new
evid
caus
relationship
viru
infect
copd
exacerb
previous
studi
demonstr
presenc
viru
singl
time
point
rise
viru
load
follow
inocul
indic
activ
viral
replic
occur
airway
tempor
relationship
appear
viru
airway
onset
symptom
airflow
obstruct
viru
clearanc
follow
resolut
clinic
ill
provid
strong
evid
causal
relationship
viru
infect
exacerb
signific
increas
neutrophil
neutrophil
elastas
neutrophil
chemokin
sputum
reduc
express
adhes
molecul
blood
neutrophil
copd
subject
mallia
et
al
lymphocyt
bronchoalveolar
lavag
copd
subject
noncopd
group
increas
follow
rhinoviru
infect
mallia
et
al
predominantli
cell
mallia
et
al
signific
relationship
peak
viru
load
sputum
peak
level
inflammatori
marker
correl
sputum
viru
load
sputum
level
tnfa
sputum
neutrophil
indic
viru
infect
drive
inflamm
exacerb
mallia
et
al
subsequ
infect
studi
replic
result
demonstr
consist
induct
exacerb
airway
inflammatori
marker
rhinoviru
infect
sever
symptomat
physiolog
inflammatori
respons
compar
noncopd
subject
unpublish
data
subject
inocul
dose
viru
via
rout
inocul
postinocul
viru
load
copd
group
higher
compar
noncopd
smoker
fig
nasal
lavag
viru
load
log
greater
statist
signific
day
suggest
immun
mechan
control
viral
replic
defici
copd
type
interferon
interferona
interferonb
type
iii
interferon
interferonk
import
mediat
innat
immun
viru
infect
respiratori
tract
examin
respons
bronchoalveolar
lavag
cell
viru
infect
infect
ex
vivo
rhinoviru
measur
interferon
product
product
interferon
respons
viru
infect
impair
bronchoalveolar
lavag
cell
copd
patient
compar
control
mallia
et
al
group
previous
identifi
defici
interferon
product
asthma
relat
outcom
follow
experiment
rhinoviru
infect
duction
respons
rhinoviru
infect
also
report
mous
model
copd
sajjan
et
al
therefor
mechan
impair
antivir
immun
copd
requir
investig
offer
new
therapeut
option
copd
exacerb
bacteri
viral
infect
common
copd
studi
examin
role
dual
virusbacteri
infect
copd
exacerb
studi
avail
report
dual
infect
minor
exacerb
cast
doubt
whether
play
signific
role
copd
exacerb
tabl
studi
collect
sampl
singl
time
point
apart
form
hutchinson
et
al
studi
patient
sampl
onset
exacerb
day
later
exacerb
viru
detect
initi
time
point
develop
secondari
bacteri
infect
patient
bacteri
exacerb
report
symptom
viral
upper
respiratori
tract
infect
prior
onset
hutchinson
et
al
therefor
studi
singl
sampl
collect
may
underestim
true
preval
dual
infect
viral
bacteri
infect
occur
concurr
carri
second
experiment
infect
studi
also
includ
group
nonsmok
use
sampl
studi
investig
relationship
rhinoviru
infect
secondari
bacteri
infect
copd
follow
rhinoviru
infect
bacteri
infect
detect
sputum
subject
copd
compar
smoker
nonsmok
mallia
et
al
moreov
wherea
peak
viru
load
occur
day
postinocul
peak
bacteri
load
day
airflow
obstruct
breathless
airway
inflamm
occur
irrespect
presenc
secondari
bacteri
infect
peak
time
initi
viral
infect
recoveri
time
prolong
subject
dual
infect
persist
day
viral
load
undetect
mallia
et
al
therefor
secondari
bacteri
infect
may
play
role
prolong
cours
virusinduc
exacerb
predomin
organ
cultur
haemophilu
influenza
streptococcu
pneumonia
use
molecular
method
bacteri
detect
demonstr
rise
bacteri
burden
signific
outgrowth
haemophilu
influenza
exist
microbiota
copd
subject
molyneaux
et
al
investig
mechan
postvir
secondari
bacteri
infect
measur
level
antimicrobi
peptid
sputum
copd
subject
develop
secondari
bacteri
infect
increas
level
neutrophil
elastas
lower
level
antimicrobi
peptid
secretori
leukoproteas
inhibitor
slpi
elafin
mallia
et
al
neutrophil
elastas
degrad
slpi
elafin
therefor
suggest
mechan
link
viru
infect
increas
suscept
bacteri
infect
copd
therefor
result
demonstr
bacteri
infect
follow
initi
viru
infect
delay
day
two
suggest
studi
collect
singl
sampl
exacerb
underestim
true
contribut
dual
virusbacteri
infect
copd
exacerb
confirm
recent
confer
abstract
georg
et
al
report
copd
exacerb
rhinoviru
detect
exacerb
onset
bacteria
frequent
detect
subsequ
sputum
sampl
peak
day
postexacerb
onset
therefor
demonstr
experiment
rhinoviru
infect
induc
clinic
featur
exacerb
copd
subject
provid
novel
vivo
evid
mechan
virusinduc
exacerb
howev
model
number
limit
ethic
reason
experiment
rhinoviru
infect
carri
subject
mild
moder
copd
wherea
patient
suscept
exacerb
sever
diseas
yet
known
whether
mechan
virusinduc
exacerb
irrespect
copd
sever
also
known
whether
exacerb
mechan
differ
accord
aetiolog
may
common
exacerb
inflammatori
pathway
mechan
may
differ
differ
virus
bacteria
noninfecti
aetiolog
air
pollut
establish
determin
whether
result
model
wide
applic
beyond
rhinoviru
infect
notwithstand
limit
evid
caus
relationship
respiratori
viru
infect
exacerb
copd
patient
indic
antivir
therapi
may
potenti
treatment
copd
exacerb
link
viru
infect
secondari
bacteri
infect
also
hold
intrigu
prospect
antivir
treatment
may
reduc
bacteri
infect
therefor
result
less
use
antibiot
current
treatment
copd
exacerb
consist
support
therapi
corticosteroid
antibiot
new
treatment
develop
past
decad
use
antibiot
base
assumpt
bacteria
main
aetiolog
agent
trigger
acut
exacerb
debat
rel
role
bacteria
efficaci
antibiot
continu
vollenweid
et
al
wedzicha
bacteri
infect
certainli
trigger
proport
exacerb
like
exacerb
benefit
antibiot
treatment
studi
biomarkerdirect
antibiot
therapi
copd
exacerb
found
patient
low
level
procalcitonin
recov
without
antibiot
use
biomarkerdirect
approach
could
reduc
antibiot
use
stolz
et
al
howev
antibiot
continu
prescrib
vast
major
copd
exacerb
contribut
develop
antibiot
resist
corticosteroid
consider
side
effect
advers
effect
everi
patient
treat
oral
corticosteroid
therefor
new
treatment
copd
exacerb
effect
safer
urgent
requir
antivir
drug
may
offer
new
therapeut
option
virusinduc
exacerb
copd
patient
better
understand
life
cycl
respiratori
virus
rhinovirus
led
identif
key
event
perotin
et
al
viral
life
cycl
develop
molecul
target
number
point
rhinoviru
life
cycl
offer
potenti
target
pharmacolog
intervent
includ
viral
attach
uncoat
viral
rna
synthesi
viral
proteas
rhinovirus
classifi
group
base
receptor
use
major
rhinoviru
serotyp
use
intercellular
adhes
receptor
major
group
rhinovirus
wherea
minor
bind
low
densiti
lipoprotein
ldl
receptor
minor
group
rhinovirus
kennedi
et
al
recent
new
group
rhinovirus
identifi
term
human
rhinoviru
speci
c
cellular
receptor
group
remain
unknown
bochkov
gern
follow
bind
cellular
receptor
conform
chang
occur
capsid
viral
entri
occur
via
endocytosi
uncoat
rhinoviru
protein
synthes
translat
viral
nucleic
acid
result
polyprotein
cleav
viral
proteas
structur
nonstructur
protein
viral
capsid
compos
outer
structur
protein
interior
protein
anchor
rna
core
capsid
number
molecul
identifi
demonstr
activ
rhinovirus
vitro
howev
major
molecul
never
progress
use
man
one
reason
lack
robust
small
anim
model
rhinoviru
infect
major
group
rhinovirus
bind
human
therefor
infect
mice
group
develop
experiment
anim
model
rhinoviru
infect
use
minor
group
virus
wildtyp
mice
major
group
virus
transgen
mice
express
human
bartlett
et
al
infect
mice
demonstr
increas
bronchoalveolar
lavag
neutrophil
lymphocyt
chemokin
cytokin
increas
viral
rna
addit
combin
rhinoviru
infect
ovalbumin
sensitis
mice
provid
model
virusinduc
asthma
exacerb
recent
demonstr
use
antibodi
mous
model
decreas
inflammatori
cell
cytokin
bronchoalveolar
lavag
lung
homogen
significantli
reduc
rhinoviru
replic
traub
et
al
model
also
use
evalu
effect
immun
recombin
rhinoviru
capsid
protein
cellular
humor
immun
respons
rhinoviru
infect
therefor
first
success
demonstr
therapeut
intervent
small
anim
model
rhinoviru
infect
hold
prospect
test
compound
vitro
activ
anim
prior
use
human
due
lack
anim
model
experiment
human
challeng
model
use
investig
vivo
effect
agent
demonstr
antivir
activ
vitro
gwaltney
hayden
et
al
hayden
et
al
levandowski
et
al
phillpott
et
al
turner
et
al
turner
et
al
major
success
limit
advers
effect
undergon
develop
howev
studi
use
experiment
rhinoviru
infect
essenti
provid
vivo
clinic
data
regard
efficaci
advers
effect
drug
activ
site
viral
proteas
highli
conserv
amongst
serotyp
homolog
mammalian
proteas
make
attract
target
antivir
therapi
viral
proteas
attract
target
antivir
drug
develop
due
essenti
role
viral
replic
uniqu
protein
structur
proteas
inhibitor
rupintrivir
identifi
highli
activ
antivir
activ
vitro
underw
clinic
assess
experiment
infect
studi
rupintrivir
prophylaxi
reduc
proport
subject
posit
viral
cultur
reduc
viral
titr
effect
frequenc
symptomat
cold
rupintrivir
treatment
commenc
h
inocul
reduc
mean
total
daili
symptom
score
significantli
reduc
viral
titer
nasal
discharg
weight
effect
frequenc
cold
hayden
et
al
base
result
rupintrivir
undergo
develop
antivir
agent
rhinoviru
infect
prevent
cellular
viru
attach
receptor
blockad
utilis
solubl
form
demonstr
antivir
effect
vitro
solubl
icam
molecul
tremacamra
develop
use
vivo
underw
clinic
trial
experiment
infect
studi
tremacamra
reduc
total
symptom
score
proport
subject
clinic
cold
reduc
viru
titer
level
nasal
lavag
fluid
turner
et
al
effect
drug
administ
either
prior
rhinoviru
challeng
howev
drug
requir
time
daili
administr
effect
minor
group
group
c
rhinovirus
utilis
receptor
cell
entri
tremacamra
undergon
clinic
develop
analysi
structur
rhinoviru
led
identif
small
hydrophob
pocket
within
beneath
icambind
region
molecul
bind
area
capsidbind
agent
induc
conform
chang
pocket
thu
hinder
virusreceptor
interact
prevent
attach
host
cell
first
drug
class
test
pirodavir
administ
time
day
via
nasal
rout
intranas
pirodavir
administ
prophylaxi
reduc
infect
rate
clinic
cold
vs
p
subject
experiment
infect
rhinoviru
treatment
commenc
h
rhinoviru
challeng
viru
shed
reduc
clinic
benefit
found
hayden
et
al
intranas
pirodavir
gener
well
toler
associ
excess
rate
transient
unpleas
tast
studi
naturallyoccur
cold
clinic
benefit
seen
pirodavir
associ
higher
rate
advers
effect
includ
nasal
dryness
nasal
bleed
unpleas
tast
hayden
et
al
pleconaril
oral
capsidbind
agent
antipicornaviru
agent
undergon
largescal
randomis
doubleblind
placebocontrol
phase
iii
trial
healthi
subject
cold
initi
experiment
infect
studi
coxsackieviru
pleconaril
significantli
reduc
viral
shed
symptom
score
schiff
sherwood
subsequ
studi
carri
naturallyacquir
cold
pleconaril
result
signific
reduct
ill
durat
significantli
shorter
time
reduct
symptom
sever
reduct
disturb
night
subject
confirm
picornaviru
infect
hayden
et
al
howev
modest
clinic
benefit
outweigh
concern
regard
risk
drug
interact
particularli
oral
contracept
pleconaril
approv
treatment
common
cold
us
food
drug
administr
senior
intranas
form
pleconaril
evalu
treatment
asthma
exacerb
result
studi
yet
publish
clinicaltrialsgov
identifi
http
wwwclinicaltrialsgov
access
octob
capsidbind
agent
vapendavir
reduc
viru
load
healthi
subject
experiment
inocul
rhinoviru
jacob
et
al
undergon
phase
ii
clinic
trial
asthmat
result
yet
publish
clinicaltrialsgov
identifi
http
wwwclinicaltrialsgov
access
august
date
drug
treatment
rhinoviru
infect
approv
clinic
use
apart
use
pleconaril
compassion
releas
basi
howev
clinic
trial
report
conduct
healthi
volunt
treatment
common
cold
pleconaril
approv
benefit
healthi
subject
felt
insuffici
outweigh
risk
patient
chronic
lung
diseas
copd
potenti
benefit
greater
treatment
may
prevent
virusinduc
exacerb
rather
cold
moreov
concern
regard
contracept
failur
less
issu
older
patient
group
therefor
riskbenefit
ratio
may
consider
favour
howev
studi
pleconaril
antivir
drug
need
carri
specif
copd
patient
determin
whether
fact
prevent
virusinduc
exacerb
data
demonstr
relationship
viru
infect
lower
respiratori
symptom
viru
load
inflammatori
marker
airway
provid
strong
theoret
basi
antivir
agent
clinic
benefit
copd
addit
observ
frequent
secondari
bacteri
infect
follow
rhinoviru
infect
hold
possibl
antivir
therapi
may
also
reduc
bacteri
infect
antibiot
use
clinic
studi
treatment
copd
exacerb
expens
time
consum
recent
studi
oral
corticosteroid
copd
exacerb
recruit
patient
hospit
year
patient
assess
elig
randomis
leuppi
et
al
studi
tnfa
antagonist
etanercept
copd
exacerb
recruit
patient
year
hospit
neg
result
aaron
et
al
therefor
even
rel
small
clinic
trial
novel
therapeut
agent
requir
consider
financi
invest
may
repres
obstacl
bring
new
therapi
market
moreov
evid
emerg
exacerb
heterogen
differ
aetiolog
inflammatori
mediat
bafadhel
et
al
respons
treatment
bafadhel
et
al
natur
infect
copd
patient
may
possibl
detect
benefici
effect
effect
antivir
drug
background
differ
rout
dose
time
exposur
viru
presenc
absenc
concurr
infect
effect
treatment
differ
time
present
etc
way
experiment
rhinoviru
infect
healthi
subject
use
assess
treatment
cold
approach
could
use
evalu
treatment
effect
virusinduc
copd
exacerb
experiment
rhinoviru
infect
copd
patient
offer
model
rout
dose
time
infect
subject
treatment
start
earli
cours
infect
therefor
mani
sourc
variabl
inher
clinic
trial
naturallyoccur
exacerb
elimin
addit
abil
carri
intens
frequent
clinic
sampl
allow
analysi
effect
treatment
larg
number
outcom
includ
symptom
lung
function
viru
load
inflammatori
marker
secondari
bacteri
infect
demonstr
treatment
reduc
symptom
viru
load
inflamm
would
provid
evid
biolog
effect
may
translat
clinic
relev
effect
convers
treatment
effect
paramet
clinic
signific
effect
unlik
addit
safeti
data
obtain
specif
patient
group
drug
aim
therefor
test
new
treatment
experiment
infect
model
potenti
demonstr
potenti
efficaci
lack
small
number
subject
rel
short
time
period
much
smaller
financi
commit
data
obtain
studi
use
inform
decis
whether
proceed
larger
clinic
trial
naturallyoccur
exacerb
experiment
rhinoviru
infect
copd
rel
new
model
studi
yet
carri
work
establish
robust
valid
safe
model
therefor
provid
basi
studi
carri
futur
new
treatment
copd
exacerb
urgent
need
link
respiratori
viru
infect
copd
exacerb
highlight
potenti
antivir
agent
treatment
virusinduc
exacerb
date
publish
studi
antivir
agent
copd
therefor
effect
unknown
experiment
rhinoviru
infect
healthi
subject
use
evalu
effect
antivir
drug
due
lack
robust
small
anim
model
develop
model
copd
exacerb
use
experiment
rhinoviru
infect
copd
establish
valid
model
virusinduc
copd
exacerb
model
could
use
evalu
new
antivir
treatment
copd
provid
evid
regard
effect
treat
virusinduc
copd
exacerb
therefor
experiment
rhinoviru
infect
copd
potenti
tool
aid
translat
develop
new
therapi
copd
exacerb
